Article Data

  • Views 533
  • Dowloads 113

Original Research

Open Access

Expression of cell cycle regulators and ki67 in patients with recurrence of early cervical cancer

  • D. Speiser1,*,
  • M. Jahn1
  • B. Ingold-Heppner2
  • M. Lanowska1
  • J.U. Blohmer1
  • U. Grittner3
  • M. Mangler1

1Department of Gynecology, Charité – Universitätsmedizin Berlin, Berlin (Germany)

2Institute of Pathology,Charité – Universitätsmedizin Berlin, Berlin (Germany)

3Department for Biostatistics and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Berlin (Germany)

DOI: 10.12892/ejgo4135.2018 Vol.39,Issue 1,February 2018 pp.76-83

Published: 10 February 2018

*Corresponding Author(s): D. Speiser E-mail: dorothee.speiser@charite.de

Abstract

Purpose of Investigation: Recurrence rates in patients with early cervical cancer are generally low. So far, no biomarker has been found to be associated with the risk of recurrence. In other carcinomas, expression of cell cycle regulators and proliferation markers like ki67 corresponded with tumour stage. The expression of those markers were examined in relapsed early cervical cancer after radical vaginal trachelectomy (RVT) to verify if they are suitable for risk stratification. Materials and Methods:We examined the expression rates of p16, p21, pRb, and cyclin D1 and ki67. Between March 1995 and March 2013, 310 patients with early cervical cancer underwent RVT as fertility-sparing surgery for early cervical cancer. Until now, ten patients suffered from recurrence. The results of relapsing and non-relapsing tumours were compared. Results: p21 was expressed heterogeneously. Neither of the relapsed adenocarcinomas showed an expression of pRb, whereas two of the recurrent squamous cell carcinomas showed positivity of pRb. Adenocarcinomas who relapsed showed a significant lower level of nuclear cyclin D1-expression (p = 0.021) than squamous cell carcinomas. Ki67 showed an expression-spectrum from 15-95% but level of expression was not significantly associated to recurrence. Conclusion: Nuclear expression of cyclin D1 was found more often in adenocarcinomas in contrast to squamous cell carcinomas. Relapsing adenocarcinomas showed higher expression of cyclin D1. Neither the examination of cell cycle regulators nor ki67 can be transferred in a clinical setting yet. Further studies based on a greater number of relapsed tumours are needed.

Keywords

Cervical cancer; Vaginal trachelectomy; Recurrence; Cell cycle regulators; ki67.

Cite and Share

D. Speiser,M. Jahn,B. Ingold-Heppner,M. Lanowska,J.U. Blohmer,U. Grittner,M. Mangler. Expression of cell cycle regulators and ki67 in patients with recurrence of early cervical cancer. European Journal of Gynaecological Oncology. 2018. 39(1);76-83.

References

[1] Check J.H., Cohen G., Cohen R., Dipietro J., Steinberg B.: “Sympathomimetic amines effectively control pain for interstitial cystitis that had not responded to other therapies”. Clin. Exp. Obstet. Gynecol., 2013, 40, 227.

[2] World Health Organization: “GLOBOCAN 2008. Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2012”. Available at: http://globocan.iarc.fr/

[3] Dargent, D., Martin, X., Sacchetoni, A. and Mathevet, P.: “Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients”. Cancer, 2000, 88, 1877.

[4] Covens A., Rosen B., Murphy J., Laframboise S., DePetrillo AD., Lickrish G. et al.: “Changes in the demographics and perioperative care of stage IA (2)/IB(1) cervical cancer over the past 16 years”. Gynecol. Oncol., 2001, 81, 133.

[5] Hertel H., Köhler C., Grund D., Hillemanns P., Possover M., Michels W., et al.: “Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. German Association of Gynecologic Oncologists (AGO)”. Gynecol Oncol., 2006, 103, 506.

[6] Quinn M.A., Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T. et al.: “Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer”. Int J Gynaecol Obstet, 2006, 95; 43–103.

[7] Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P., et al.: “Carcinoma of the cervix uteri”. J. Epidemiol. Biostat., 2001, 6, 7.

[8] Dargent D., Brun J.L., Roy M., Mathevet P., Remy I.: “La trachélectomie élargie (T.E.) une alternative à l’hystérectomie radicale dans le traitement des cancers infiltrants développés sur la face externe du col utérin“. Jobgyn., 1994, 2, 285.

[9] Lanowska M., Mangler M., Spek A., Grittner U., Hasenbein K., Chiantera V. et al.: „Radical Vaginal Trachelectomy (RVT) Combined With Laparoscopic Lymphadenectomy: Prospective Study of 225 Patients With Early-Stage Cervical Cancer”. Int. J. Gynecol. Cancer, 2011, 21, 1458.

[10] Speiser D., Mangler M., Köhler C., Hasenbein K., Hertel H., Chiantera V., et al.: “Fertility outcome after radical vaginal trachelectomy: a prospective study of 212 patients”. Int. J. Gynecol. Cancer, 2011, 21, 1635.

[11] Rob L., Skapa P., Robova H.: “Fertility-sparing surgery in patients with cervical cancer”. Lancet Oncol., 2011, 12, 192.

[12] Mangler M., Lanowska M., Köhler C., Vercellino F., Schneider A., Speiser D.: “Patterns of cancer recurrence in 320 patients after radical vaginal trachelectomy”. Int. J. Gynecol. Cancer, 2014, 24, 130.

[13] Diaz J.P., Sonoda Y., Leitao M.M., Zivanovic O., Brown C.L., Chi D.S., et al.: “Oncologic outcome of fertility sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma”. Gynecol. Oncol., 2008, 111, 255.

[14] Whitney C.W., Stehman F.B.: “The abandoned radical hysterectomy: a Gynecologic Oncology Group Study”. Gynecol. Oncol., 2000, 79, 350.

[15] Alfsen G.C., Reed W., Sandstad B., Kristensen G.B., Abeler V.M.: “The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of Gynaecology and obstetrics stage I and II adenocarcinoma.” Cancer, 2003, 98, 1880.

[16] Betticher D.C., Heighway J., Hasleton P.S., Altermatt H.J., Ryder W.D., Cerny T. et al.: “Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer”. Br. J. Cancer, 1996, 73, 294.

[17] McClelland R.A., Gee J.M., O’Sullivan L., Barnes D.M., Robertson J.F., Ellis I.O. et al.: “p21(WAF1) expression and endocrine response in breast cancer”. J. Pathol., 1999, 188, 126.

[18] Viale G., Pellegrini C., Mazzarol G., Maisonneuve P., Silverman M.L., Bosari S.: “p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations”. J. Pathol., 1999, 187, 302.

[19] van de Putte G., Holm R., Lie A.K., Tropé C.G., Kristensen G.B.: “Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis”. Gynecol Oncol., 2003, 89, 140.

[20] Sherr C.J., Roberts J.M.: “CDK inhibitors: positive and negative regulators of G1-phase progression”. Genes Dev., 1999, 13, 1501.

[21] Pinto A.P., Degen M., Villa L.L., Cibas E.S.: “Immunomarkers in gynecologic cytology: the search for the ideal ‘biomolecular Papanicolaou test’”. Acta Cytol., 2012, 56, 109.

[22] Michalides R.J., van Veelen N.M., Kristel P.M., Hart A.A., Loftus B.M., Hilgers F.J., et al.: “Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck”. Arch. Otolaryngol. Head Neck Surg., 1997, 123, 497.

[23] Ishikawa T., Furihata M., Ohtsuki Y., Murakami H., Inoue A., Ogoshi S.: “Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma”. Br. J. Cancer, 1998, 77, 92.

[24] Bae D.S., Cho S.B., Kim Y.J., Whang J.D., Song S.Y., Park C.S., et al.: “Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus”. Gynecol. Oncol., 2001, 81, 341.

[25] Little L., Stewart C.J.: “Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions”. Mod. Pathol., 2010, 23, 611.

[26] Sherr C.J., Roberts J.M.: “Inhibitors of mammalian G1 cyclin-dependent kinases”. Genes Dev., 1995, 9, 1149.

[27] Huang L.W., Chou Y.Y., Chao S.L., Chen T.J., Lee T.T.: “p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome”. Gynecol. Oncol., 2001, 83, 348.

[28] Lu X., Toki T., Konishi I., Nikaido T., Fujii S.: “Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis”. Cancer, 1998, 82, 2409.

[29] Chellappan S.P., Hiebert S., Mudryj M., Horowitz J.M., Nevins J.R.: “The E2F transcription factor is a cellular target for the RB protein”. Cell, 1991, 65, 1053.

[30] de Riese W., Allhoff E., Stief C.G., Lenis G., Schlick R., Liedke S., et al.: “In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a”. Urol. Res, 1991, 19, 87.

[31] Milde-Langosch K., Riethdorf S.: “Role of cell-cycle regulatory proteins in gynecological cancer”. J. Cell. Physiol., 2003, 196, 224.

[32] Salvesen H.B., Das S., Akslen L.A.: “Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis”. Clin. Cancer Res., 2000, 6, 153.

[33] Tringler B., Gup C.J., Singh M., Groshong S., Shroyer A.L., Heinz D.E., et al.: “Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia”. Hum. Pathol., 2004, 35, 689.

[34] Cheung T.H., Lo K.W., Yu M.M., Yim S.F., Poon C.S., Chung T.K., et al.: “Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma”. Cancer Lett., 2001, 172, 93.

[35] Skomedal H., Kristensen G.B., Lie A.K., Holm R.: “Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas”. Gynecol. Oncol., 1999, 73, 223.

[36] Nichols G.E., Williams M.E., Gaffey M.J., Stoler M.H.: “Cyclin D1 gene expression in human cervical neoplasia”. Mod. Pathol., 1996, 9, 418.

[37] Portari E.A., Russomano F.B., de Camargo M.J., Machado Gayer C.R., da Rocha Guillobel H.C., Santos-Rebouças C.B., et al.: “Immunohistochemical expression of cyclin D1, p16Ink4a, p21WAF1, and Ki-67 correlates with the severity of cervical neoplasia”. Int J Gynecol. Pathol., 2013, 32, 501.

[38] Hanprasertpong J., Tungsinmunkong K., Chichareon S., Wootipoom V., Geater A., Buhachat R., et al.: “Correlation of p53 and Ki-67 (MIB-1) expressions with clinicopathological features and prognosis of early stage cervical squamous cell carcinomas”. J. Obstet. Gynaecol. Res., 2010, 36, 572.

[39] Oka K., Nakano T., Hoshi T.: “Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices”. Cancer, 1996, 77, 2280.

[40] Vosmik M., Laco J., Sirak I., Beranek M., Hovorkova E., Vosmikova H., et al.: “Prognostic significance of human papillomavirus (HPV) status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on outcome after (chemo-) radiotherapy in patients with squamous cell carcinoma of uterine cervix”. Pathol. Oncol. Res., 2014, 20, 131.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top